These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


209 related items for PubMed ID: 9215300

  • 21. Effects of free fatty acids and acipimox, a lipolysis inhibitor, on the somatotroph responsiveness to GHRH in anorexia nervosa.
    Gianotti L, Fassino S, Daga GA, Lanfranco F, De Bacco C, Ramunni J, Arvat E, MacCario M, Ghigo E.
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):713-20. PubMed ID: 10848875
    [Abstract] [Full Text] [Related]

  • 22. Diagnosis of growth hormone deficiency after pituitary surgery: the combined acipimox/GH-releasing hormone test.
    van Dam PS, Dieguez C, Cordido F, de Vries WR, Veldhuyzen BF, van Thiel E, Casanueva FF, Koppeschaar HP.
    Clin Endocrinol (Oxf); 2003 Feb; 58(2):156-62. PubMed ID: 12580930
    [Abstract] [Full Text] [Related]

  • 23. Acute pharmacologic blockade of lipolysis normalizes nocturnal growth hormone levels and pulsatility in obese subjects.
    Andreotti AC, Lanzi R, Manzoni MF, Caumo A, Moreschi A, Pontiroli AE.
    Metabolism; 1994 Oct; 43(10):1207-13. PubMed ID: 7934970
    [Abstract] [Full Text] [Related]

  • 24. Free fatty acids block growth hormone (GH) releasing hormone-stimulated GH secretion in man directly at the pituitary.
    Casanueva FF, Villanueva L, Dieguez C, Diaz Y, Cabranes JA, Szoke B, Scanlon MF, Schally AV, Fernandez-Cruz A.
    J Clin Endocrinol Metab; 1987 Oct; 65(4):634-42. PubMed ID: 2888782
    [Abstract] [Full Text] [Related]

  • 25. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary manipulation in obese and nonobese subjects.
    Kelijman M, Frohman LA.
    J Clin Endocrinol Metab; 1988 Mar; 66(3):489-94. PubMed ID: 3127415
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Plasma free fatty acids and serum insulin in subjects feeding at 12-hour intervals; effects of methionyl growth hormone and of acipimox, an inhibitor of lipolysis.
    Pontiroli AE, Lanzi R, Monzani M, Musatti L, Guglielmone C, Pozza G.
    J Endocrinol Invest; 1992 Feb; 15(2):85-91. PubMed ID: 1569294
    [Abstract] [Full Text] [Related]

  • 28. Short term continuous intravenous infusion of growth hormone (GH) inhibits GH-releasing hormone-induced GH secretion: a time-dependent effect.
    Rosenthal SM, Kaplan SL, Grumbach MM.
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1101-5. PubMed ID: 2498383
    [Abstract] [Full Text] [Related]

  • 29. Effect of acute pharmacological modulation of plasma free fatty acids on GH secretion in acromegalic patients.
    Cordido F, Peñalva A, Martinez T, Casanueva FF, Dieguez C.
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):509-13. PubMed ID: 11318787
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Impaired inhibitory effects of somatostatin on growth hormone (GH)-releasing hormone stimulation of GH secretion after short term infusion.
    Kelijman M, Frohman LA.
    J Clin Endocrinol Metab; 1990 Jul; 71(1):157-63. PubMed ID: 1973420
    [Abstract] [Full Text] [Related]

  • 32. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M, Tassone F, Gianotti L, Lanfranco F, Grottoli S, Arvat E, Muller EE, Ghigo E.
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [Abstract] [Full Text] [Related]

  • 33. Corticotropin-releasing hormone inhibition of growth hormone-releasing hormone-induced growth hormone release in man.
    Barbarino A, Corsello SM, Della Casa S, Tofani A, Sciuto R, Rota CA, Bollanti L, Barini A.
    J Clin Endocrinol Metab; 1990 Nov; 71(5):1368-74. PubMed ID: 2229294
    [Abstract] [Full Text] [Related]

  • 34. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy.
    Vance ML, Kaiser DL, Martha PM, Furlanetto R, Rivier J, Vale W, Thorner MO.
    J Clin Endocrinol Metab; 1989 Jan; 68(1):22-8. PubMed ID: 2491864
    [Abstract] [Full Text] [Related]

  • 35. Mediation of the hepatic effects of growth hormone by its lipolytic activity.
    Piatti PM, Monti LD, Caumo A, Conti M, Magni F, Galli-Kienle M, Fochesato E, Pizzini A, Baldi L, Valsecchi G, Pontiroli AE.
    J Clin Endocrinol Metab; 1999 May; 84(5):1658-63. PubMed ID: 10323396
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.
    Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR.
    J Clin Endocrinol Metab; 1992 Aug; 75(2):530-5. PubMed ID: 1379256
    [Abstract] [Full Text] [Related]

  • 38. Effects of lowering circulating free fatty acid levels on protein metabolism in adult growth hormone deficient patients.
    Nielsen S, Jørgensen JO, Hartmund T, Nørrelund H, Nair KS, Christiansen JS, Møller N.
    Growth Horm IGF Res; 2002 Dec; 12(6):425-33. PubMed ID: 12423628
    [Abstract] [Full Text] [Related]

  • 39. The effect of free fatty acids on growth hormone (GH)-releasing hormone-mediated GH secretion in man.
    Imaki T, Shibasaki T, Shizume K, Masuda A, Hotta M, Kiyosawa Y, Jibiki K, Demura H, Tsushima T, Ling N.
    J Clin Endocrinol Metab; 1985 Feb; 60(2):290-3. PubMed ID: 3917457
    [Abstract] [Full Text] [Related]

  • 40. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L, Maccario M, Lanfranco F, Ramunni J, Di Vito L, Grottoli S, Muller EE, Ghigo E, Arvat E.
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 11.